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ABSTRACT
Aim. To investigate the feasibility of using bevacizumab
to improve the survival of American Joint Committee on
Cancer (AJCC) stage III melanoma patients, we investi-
gated how a single bevacizumab treatment affected nodal
disease and a panel of biomarkers in clinically ﬂuorode-
oxyglucose positron emission tomography (FDG-PET)/
computed tomography (CT)-staged, stage III melanoma
patients, prior to therapeutic lymph node dissection
(TLND).
Methods. Four weeks before TLND, nine patients (med-
ian age 50, range 28.8–62.1 years; two male, seven female)
with palpable lymph node metastases received 7.5 mg/kg
bevacizumab. Before and after this treatment, all patients
were assessed by measurements of the maximum stan-
dardized uptake value (SUVmax) by FDG-PET scan, and
serum S-100B and lactate dehydrogenase (LDH). After
TLND, the dissection specimen was analyzed for number
of removed lymph nodes, number of metastatic lymph
nodes, and tumor necrosis.
Results. Median follow-up was 15.5 (2.2–32.9) months.
Histopathological analysis revealed tumor necrosis in six
patients, of whom ﬁve had an S-100B decline and one had
an unchanged S-100B level after bevacizumab. The other
three patients showed an S-100B increase and no necrosis.
Tumor necrosis was correlated with S-100B decrease
(P = 0.048). No association was found between necrosis
and the markers SUVmax and LDH. No wound healing
disturbances were encountered.
Conclusion. Tumor necrosis in dissection specimens was
associated with declining S-100B levels, while elevated
S-100B was only found in cases with no necrosis. Bev-
acizumab might be useful in treating AJCC stage III
melanoma patients prior to TLND, and S100-B appears to
be a useful marker for assessment of treatment effects.
Melanoma is an aggressive and highly metastatic dis-
ease, which can be fatal with a rapid systemic
dissemination. Approximately one-third of all melanoma
patients will experience disease recurrence.
1,2 While
almost all organs can be involved, the most frequent target
sites are the liver, bone, and the brain. Treatment results for
advanced melanoma remain unsatisfactory. No systemic
therapy has been demonstrated to affect overall survival,
although recent studies of immunotherapy with ipilimumab
and the introduction of BRAF pathway inhibitors have
shown promising results.
3–5 For melanoma patients with
nodal disease, therapeutic lymph node dissection (TLND),
with or without adjuvant radiation, remains the only
curative therapy, with 5-year survival rates of 78, 59, and
40%, respectively, for patients with AJCC stage IIIA, IIIB,
and IIIC disease.
6,7 As a consequence of shortages in
healthcare resources, the growing elderly population in the
Western world, and the increasing incidence of cancer, the
wait time for surgery at some cancer centers has lengthened
to an average of 4–5 weeks. This period before TLND
offers a unique opportunity to test novel induction treat-
ments before surgery.
Tumor angiogenesis is a continuous process that allows
cancer cells to grow by supplying the tumor with nutrients
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providing a route for metastatic spread.
8,9 Vascular endo-
thelial growth factor A (VEGF-A) is a key growth factor
involved in the development and maintenance of tumor
angiogenesis.
10 Bevacizumab, a fully humanized mono-
clonal antibody, binds to all VEGF isoforms with high
afﬁnity, thereby blocking ligand–receptor signaling.
11 It is
currently used in patients with metastatic colon cancer,
non-small-cell lung cancer, and renal cell cancer.
12–14
Bevacizumab was previously evaluated in a randomized
phase II trial (BEAM trial) in metastatic melanoma, which
compared the effects of the combination of carboplatin and
paclitaxel, with and without bevacizumab. The addition of
bevacizumab had a signiﬁcant impact on progression-free
survival, and some impact on overall survival, although
this effect was not signiﬁcant.
15
The time spent waiting for a TLND for regional meta-
static disease could be used more effectively if an induction
therapy could be safely administered to reduce tumor load
before surgery. S-100B and SUV are known to be of
prognostic value in stage III melanoma; elevated S-100B
and SUV in stage III melanoma patients can be speciﬁc
indicators of disease progression.
16–22 Therefore, we
hypothesized that monitoring S-100B and SUV before and
after a single bevacizumab treatment might provide a
‘‘measurable reﬂection’’ of the response to this angiogenic
treatment.
Here, we investigated the feasibility of using serum
biomarkers, S-100B and LDH, and the standardized uptake
value (SUV) from FDG-PET to evaluate effects of an
induction treatment with a single dose of bevacizumab in
stage IIIB/C melanoma patients, prior to TLND. We
assessed the perioperative changes in biomarker levels
following bevacizumab treatment, as well as the induction
of tumor necrosis based on ﬁnal histopathology of the
resected lymph nodes.
PATIENTS AND METHODS
Patients
All consecutive melanoma patients presenting with
palpable and cytology-proven lymph node metastases
(AJCC IIIB/C) at the University Medical Centre Groningen
(UMCG) between January and July 2008 were evaluated
with FDG-PET and spiral CT in addition to routine staging,
which included a complete medical history, physical
examination, and blood chemistry proﬁle. If the FDG-PET
and CT were negative for distant metastases, patients were
offered participation in the bevacizumab trial bridging the
waiting time between diagnosis and TLND. Eligible
patients were C18 years of age with AJCC stage IIIb
melanoma and World Health Organization (WHO) per-
formance status of 0–2. Exclusion criteria included history
of radiotherapy to the involved lymph node basin, major
surgery within 28 days of start of the study, administration
of any investigational drug within 30 days before start of
the study, and clinical evidence of brain metastases.
Patients who presented with positive sentinel lymph node
biopsy, local recurrence, and/or in-transit disease were also
excluded from this study. Examined data included patient
demographics, primary tumor characteristics, date and type
of operation, and status at last follow-up. Patients with
nodal metastases of C3 cm and/or C3 positive lymph
nodes and/or extranodal (EN) disease received adjuvant
radiotherapy (20 9 2.4 Gy).
This study was approved by the local medical ethics
committee, and written informed consent was obtained
from all participants. The study was registered under trial
number NTR1941 and was organized as a corollary study
in concurrence with another feasibility study investigating
the presence of VEGF in melanoma lesions by VEGF-
single-photon emission computed tomography (SPECT)
with
111In-bevacizumab.
23
Study Design
On day 0, all selected patients were evaluated with a
FDG-PET scan, and on day 7, they received a single dose
of 7.5 mg/kg bevacizumab intravenously. On day 40, the
patients underwent a second FDG-PET scan, after which
TLND was performed on day 42 (5 weeks after bev-
acizumab). S-100B and LDH levels were measured on days
0, 41, and 43 (ﬁrst visit to outpatient clinic, 1 day preop-
eratively, and 1 day postoperatively). After lymph node
dissection, the pathological results were analyzed.
S-100B
Concentrations of serum S-100B were measured using
the Liason Sangtec 100 immunoassay on an Advantage
(Nichols). The half-life of S-100B is estimated to be about
30 min.
24 Levels were calculated using a calibration curve
and checked against internal standards with known con-
centrations of S-100B. In this assay, concentrations were
considered normal if they were below a cutoff point of
0.15 lg/l. Concentrations above this range were considered
to be elevated. For all patients, the change in S-100B
concentration from day 0 to day 41 was determined.
LDH
LDH was routinely analyzed by enzymatic activity
measurement with a Roche Modular analyzer (Hitachi).
LDH values\250 U/l were considered to be normal.
Bevacizumab Effect in AJCC Stage III Melanoma 621Standardized Uptake Value (SUV)
To assess the degree of FDG accumulation before and
after bevacizumab treatment, the maximum standardized
uptake value (SUVmax) was calculated from a FDG-PET
scan. The SUV depends on the amount of injected radio-
activity, the patient’s weight, and the calibration factor of
the camera, and it is calculated according to the following
formula: SUVmax = radioactivity concentration in tissue
(Bq/kg)/(injected dose [Bq]/patient weight [kg]). If multi-
ple metastases were present in the lymph node basin, the
lesion with the most intense uptake was chosen. The cutoff
point for SUV is data driven and therefore depends on the
patient group; there is no consensus in the literature
regarding a cutoff point for SUV.
25–27 In the present study,
any decrease/increase of SUVmax was recorded simply as
the level of decrease/increase.
Surgery
The therapeutic axillary lymph node dissection included
a level III resection with resection of the pectoralis minor
muscle. The groin lymph node dissection included a
superﬁcial (inguinal) and deep (iliac-obturatory) groin
dissection. The latter procedure was performed as exten-
sively described by Baas et al.
28 Perioperative surgical
complications, number of harvested lymph nodes, number
of metastatic lymph nodes, maximum metastasis diameter,
and degree of tumor necrosis were scored. The pathological
results after lymph node dissection were analyzed by a
pathologist.
Statistics
Fisher’s exact test was used to assess associations
between the SUV, S-100B and LDH levels, and pathology
data.
RESULTS
Patient Characteristics
Table 1 presents the characteristics of the nine AJCC
stage III melanoma patients, who included two males and
seven females, with median age of 50 (range 28.8–62.1)
years. Median follow-up time was 15.5 (range 2.2–32.9)
months. In these nine patients, metastatic lymph nodes
were detected with spiral CT and FDG-PET imaging. After
TLND, the resection specimens displayed a median of 16
nodes (range 8–29). No perioperative or wound healing
disturbances were encountered.
SUV and LDG
In ﬁve of the nine patients, SUVmax decreased after
bevacizumab treatment. In one patient, SUVmax was not
inﬂuenced, and in the remaining three patients, SUVmax
increased. Between day 0 and day 41, an LDH decrease
was noted in seven patients and an elevation in two
patients.
S-100B and Pathology
The pathologic analysis reported tumor necrosis in six
TLND specimens after bevacizumab treatment. In ﬁve of
these six patients, a decrease in S-100B after bevacizumab
was documented on day 41; in the remaining one patient,
S-100B was unchanged but was comparatively decreased
on day 43. Tumor necrosis was signiﬁcantly associated
TABLE 1 Characteristics of the primary melanoma and localization
of recurrence of the nine patients in the study
Number %
Sex
Male 2 22.2
Female 7 77.8
Age, years, median (range)
50.0 (28.8–62.1) – –
Localization of primary melanoma
Trunk 5 55.6
Upper extremities 0 0
Lower extremities 3 33.3
Unknown 1 11.1
Clark level
II 1 11.1
III 2 22.2
IV 5 55.6
Unknown primary 1 11.1
Breslow thickness (mm)
B1.0 4 44.4
[1.0 4 44.4
Unknown primary 1 11.1
Mitotic index (n)
B5 4 44.4
C6 4 44.4
Unknown primary 1 11.2
Ulceration
Yes 3 33.3
No 5 55.6
Unknown primary 1 11.1
Localization of lymph node metastases
Axilla 5 55.6
Groin 4 44.4
622 S. Kruijff et al.with declining S-100B levels (P = 0.048). These data are
presented in Table 2 and Fig. 1. No association was found
between the markers SUVmax and S-100B (P = 0.6) or
LDH, nor was a correlation found between LDH or
SUVmax and necrosis (Fig. 2).
DISCUSSION
This is the ﬁrst study to assess the use of biomarkers to
monitor the response following an induction treatment with
bevacizumab, a VEGF-speciﬁc antibody, prior to TLND in
AJCC stage III melanoma patients with nodal disease. Our
data suggest that neoadjuvant bevacizumab may be useful
for preoperative tumor load reduction before TLND in
AJCC stage IIIB/C melanoma patients.
Neoadjuvant treatment with bevacizumab might have
induced tumor necrosis in the metastatic lymph nodes in
six of the nine patients. In all patients with necrosis in the
dissection specimen, a signiﬁcant decline of serum S-100B
levels was observed. In contrast, in patients whose S-100B
levels continued to rise following treatment, no necrosis
was found in the dissection preparations. No relationship
was found between SUV and S-100B or LDH and S-100B
or any of the other pathological data.
The data from this feasibility study should only be
considered preliminary, and it is clear that no ﬁrm con-
clusions can be drawn from such a small group of samples.
However, the observations certainly indicate that further
investigation is warranted. The data from the present study
might indicate that a single neoadjuvant bevacizumab
treatment induced tumor necrosis in the tumor-bearing
lymph nodes. Even more importantly, a decline of S-100B
was observed in all patients who exhibited tumor necrosis
after induction therapy.
TABLE 2 Association
between pathology data and
changes in SUV value, S-100B,
and LDH
S-100B in lg/l
Patients: n = 9
a P\0.05 (Fisher’s exact test)
SUV S-100B LDH
Increase (%) Decrease (%) Increase (%) Decrease (%) Increase (%) Decrease (%)
Size
B4.0 cm 3 (75) 1 (20) 2 (50) 2 (40) 1 (50) 3 (43)
[4.0 cm 1 (25) 4 (80) 2 (50) 3 (60) 1 (50) 4 (57)
Necrosis
Yes 3 (75) 3 (60) 1 (25)
a 5 (100)
a 0 (0) 6 (86)
No 1 (25) 2 (40) 3 (75) 0 (0) 2 (100) 1 (14)
Ratio positive/removed nodes
B0.5 2 (50) 2 (40) 2 (50) 2 (40) 1 (50) 3 (43)
[0.5 2 (50) 3 (60) 2 (50) 3 (60) 1 (50) 4 (57)
Extranodal growth
No 2 (50) 3 (60) 3 (75) 2 (40) 1 (50) 4 (57)
Yes 2 (50) 2 (40) 1 (25) 3 (60) 1 (50) 3 (43)
Total 4 (44) 5 (56) 4 (44) 5 (56) 2 (22) 7 (78)
9
8
7
6
5
4
3
2
1
10
S-100B in µg/L
1
0.12 0.10
2
0.32 0.06
3
3.21
2.66
4
0.29 0.08
5
1.48
0.70
6
0.07 0.07
7
1.12
8
0.75
1.78
9
0.04 1.78
Patients: n = 9 FIG. 1 S-100B before and
after bevacizumab
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often necrosis is discovered after lymph node dissection
without prior administration of any induction therapy.
However, the relatively high necrosis rate within our small
sample of patients and the related S-100B decline might
suggest a drug-induced tumor necrosis in the lymph nodes.
The associated signiﬁcant decrease of tumor load might
explain the S-100B decline in all six patients.
To date, the most extensively studied biomarker in
melanoma is S-100B, a 21-kDa protein that was ﬁrst iso-
lated from the central nervous system in vertebrates.
S-100B is located in the cytoplasm and nucleus in cells of
neuroectodermal origin, e.g., melanocytes. S-100B has
various intracellular functions, mainly in cytoskeleton
integrity, cell cycle regulation, and apoptosis. Elevated
serum S-100B occurs as the result of loss of melanoma cell
integrity.
24 The mechanism by which this protein is
released into circulation remains uncertain, but it is prob-
ably caused by cell damage or apoptosis. The hypothesis
that elevation of S-100B should be interpreted as indicating
ongoing metastatic disease has been suggested by earlier
data.
16 Proportions of patients with elevated S-100B
concentrations are 0–9% in stage I/II, 5–98% in stage III,
and 40–100% in stage IV melanoma.
29 For clinically FDG-
PET and CT-staged stage III patients, a preoperatively
elevated S-100B level is correlated with decreased sur-
vival.
16–19 In stage IV, improved survival is observed for
patients with low S-100B levels; increased concentrations
of S-100B during systemic treatment are associated with
disease progression.
30–34 Recently, Bouwhuis et al.
revealed that elevation of S-100B levels throughout serial
serum measurements in stage III is of very signiﬁcant
prognostic value, which was even stronger when combined
with disease stage and number of positive lymph nodes.
35
However, elevated S-100B should not only be seen as a
prognostic factor for survival and a mere reﬂection of
disease progression alone; the presence of the protein
S-100B itself induces disease progression as well. S-100B
interacts with p53 and thereby downregulates its function
as a tumor suppressor protein by preventing induction of
apoptosis of potential melanoma cells.
36,37
Taking these results into account, an induction therapy
before lymph node dissection might interrupt the mela-
noma proliferation cycle in two ways: ﬁrst by reducing
FIG. 2 Patient (61 years, female),
melanoma lower extremities (Breslow
2.1 mm, ulceration). Inguinal lymph
nodes metastases with a SUVmax of 9.2
ﬁrst scan and 10.5 second scan
624 S. Kruijff et al.tumor load, and second by temporarily suppressing serum
S-100B concentrations and thus preventing downregulation
of tumor suppressor protein p53. Bevacizumab as an
induction therapy might temporarily suppress metastatic
proliferation and eventually, in combination with surgery,
improve outcome.
Antiangiogenic therapy is a promising strategy in the
treatment of cancer. Angiogenesis, or remodeling of an
existing network of blood vessels, performs an essential
role in diverse pathophysiological processes.
38,39 Because
the neovascularization process that supports tumor growth
may be similar to that involved in physiological wound
healing, a delay in wound repair has been a concern. This
may be one of the reasons that bevacizumab has not been
widely used as induction therapy before major surgical
cancer treatment.
40 None of the patients in our study
showed any would healing disturbances during the course
of the study.
The ongoing AVAST-M trial is the only known ran-
domized trial evaluating the VEGF inhibitor, bevacizumab,
for adjuvant therapy following resection of AJCC stage IIB
(T4aN0M0), IIC (T4bN0M0), and III (TxN1–3M0) cutaneous
melanoma. Many randomized trials of adjuvant therapy
have been performed in patients after resection of mela-
noma, but to date, no treatment has convincingly improved
overall survival. The AVAST-M trial is a Cancer Research
UK-funded, National Cancer Research Network (NCRN)
trial in which patients with previously resected melanoma
at high risk of disease recurrence will be randomized to
receive either standard observation or bevacizumab
administration for 1 year.
41
In one of the few examples in which induction therapy
effects were monitored by biomarkers, Willet et al. per-
formed a phase I–II trial to test the efﬁcacy of adding
bevacizumab to standard chemoradiotherapy as an induc-
tion therapy before rectal surgery. The phase II clinical trial
involved administration of neoadjuvant bevacizumab, in
combination with 5-ﬂuorouracil (5-FU) and radiation
therapy. The response of one patient’s tumor to this regi-
men with bevacizumab was dramatic, with no residual
cancer in the surgical specimen. More surprisingly, plasma
carcinoembryonic antigen (CEA) dropped substantially
from a pretreatment value of 122.8–63.6 ng/ml at 12 days
after the ﬁrst bevacizumab infusion, and declined to
4.9 ng/ml at 1 month after completion of neoadjuvant
therapy before surgery.
42
In addition to S-100B, we also monitored SUVmax and
LDH levels in the patients in this study, but did not ﬁnd any
signiﬁcant correlation between these values and S-100B or
pathology ﬁndings. In an earlier study, no relation was
found between the prognostic markers S-100B and SUV in
melanoma patients with palpable lymph nodes.
43 Evidence
concerning FDG uptake suggests that intensity of uptake
does not correlate with lymph node tumor burden, but more
with biological aggressiveness.
44 Serum lactate dehydro-
genase (LDH) has high speciﬁcity for melanoma but low
sensitivity; it is an independent prognostic factor in stage
IV melanoma.
16 Taking these facts into consideration, it is
not surprising that we observed a lack of correlation of
these markers with tumor response in this study.
In conclusion, this feasibility study has shown that
induction treatment with bevacizumab in stage III mela-
noma 4 weeks prior to surgery may be related to induction
of tumor necrosis without any observed incidence of
wound healing disturbance. More importantly, when tumor
necrosis was found in the dissection preparation, a 100%
decline of S-100B was noted. Correspondingly, absence of
tumor necrosis was correlated with ongoing S-100B ele-
vation. The ability to target therapy towards well-selected
subgroups of patients with the use of biomarkers, such as
S-100B, could increase the likelihood of beneﬁt and might
improve therapeutic outcomes for future melanoma treat-
ments.
45 Induction treatment with bevacizumab followed
by therapeutic lymph node dissection could be a potentially
successful combined treatment and might improve locore-
gional control, and therefore disease-free survival, for
lymphogenic disseminated melanoma patients.
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